Xilio Therapeutics reported a quarterly loss of $0.58 per share, beating the Zacks Consensus Estimate for a $0.66 loss and improving from a $2.52 loss per share a year ago. The narrower loss suggests better-than-expected operating performance and a significant year-over-year improvement, though the company remains unprofitable.
Xilio Therapeutics reported a quarterly loss of $0.58 per share, beating the Zacks Consensus Estimate for a $0.66 loss and improving from a $2.52 loss per share a year ago. The narrower loss suggests better-than-expected operating performance and a significant year-over-year improvement, though the company remains unprofitable.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
